BPG is committed to discovery and dissemination of knowledge
Retrospective Study
©The Author(s) 2026.
World J Gastroenterol. Feb 21, 2026; 32(7): 115406
Published online Feb 21, 2026. doi: 10.3748/wjg.v32.i7.115406
Table 1 Baseline characteristics of primary intestinal diffuse large B-cell lymphoma patients in the SEER training cohort before and after propensity score matching, n (%)
CharacteristicsBefore propensity score matching
After propensity score matching
Right side (n = 3358)
Left side (n = 474)
SMD
Right side (n = 1063)
Left side (n = 474)
SMD
Age0.0710.004
< 50493 (14.7)64 (13.5)155 (14.6)64 (13.5)
50-691269 (37.8)168 (35.4)396 (37.3)168 (35.4)
70-891486 (44.2)225 (47.5)477 (44.9)225 (47.5)
≥ 90110 (3.3)17 (3.6)35 (3.3)17 (3.6)
Gender0.0100.006
Female1263 (37.6)176 (37.1)396 (37.3)176 (37.1)
Male2095 (62.4)298 (62.9)667 (62.7)298 (62.9)
Race0.0600.039
White2787 (83.0)403 (85.0)889 (83.6)403 (85.0)
Black177 (5.3)24 (5.1)55 (5.2)24 (5.1)
Other394 (11.7)47 (9.9)119 (11.2)47 (9.9)
Stage0.056< 0.001
Stage I/II2464 (73.4)336 (70.9)749 (70.5)336 (70.9)
Stage III/IV894 (26.6)138 (29.1)314 (29.5)138 (29.1)
Radiation0.2840.002
Yes192 (5.7)67 (14.1)128 (12.0)67 (14.1)
No/unknown3166 (94.3)407 (85.9)935 (88.0)407 (85.9)
Surgery0.5810.001
Yes2225 (66.3)182 (38.4)477 (44.9)182 (38.4)
No1133 (33.7)292 (61.6)586 (55.1)292 (61.6)
Chemotherapy0.0990.002
Yes2481 (73.9)329 (69.4)760 (71.5)329 (69.4)
No/unknown877 (26.1)145 (30.6)303 (28.5)145 (30.6)


Write to the Help Desk